Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Type 1 Interferon as a Master Regulator for Tumor Immunosupression

EF 2018-19

Résumé
Currently, chemotherapy is the standard for cancer therapies in the health care industry, even with its large array of negative side effects. Immunotherapy has the potential to replace chemotherapy as the primary method of cancer treatment. Oncolytic viral vaccines (OVV) are one such therapy showing promise and undergoing rigorous clinical development. OVVs are viruses that are harmless to healthy cells while targeting and attacking tumor cells. OVVs are made with a specific molecule that is also produced by tumors – because immune cells can recognize the OVV as an invader, they will then be able to recognize the tumor by picking up the commonly shared molecule from the OVV, and denote it as a threat creating a immune response against the tumor. OVVs are also known to induce a molecule known as type I interferon (IFN-I). In non-cancerous conditions, IFN-I induces the maturation of a multitude of immune cells, strengthening an immune response. In cancerous conditions, IFN-I can prevent tumor cell growth by promoting death of said tumor cells. However, it is also seen that IFN-I can also play a negative role during T cell-mediated response. In particular, IFN-I can lead to the creation of a surrounding environment that prevents the immune system from fighting cancer, a mechanism known as immunosuppression and is a significant hurdle in cancer immunotherapy. Recently, it has been demonstrated that IFN-I, despite its role as an immune system mediator, may not be needed during treatment with OVVs and in high concentrations, may be deleterious to the health of the individual. Accordingly, this project will explore the effects of IFN-I on the environment produced by the tumor as well as the effect it has on immune cell function in the context of OVV therapies.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
418425
Name
Fisher Robert
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Type 1 Interferon as a Master Regulator for Tumor Immunosupression
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adaptive T-Cell Therapy; Checkpoint Blockade; Immunotherapy; Interferon; Memory T-Cell; Oncolytic Viral Vaccine; Tumor Subversion
Abstract
Currently, chemotherapy is the standard for cancer therapies in the health care industry, even with its large array of negative side effects. Immunotherapy has the potential to replace chemotherapy as the primary method of cancer treatment. Oncolytic viral vaccines (OVV) are one such therapy showing promise and undergoing rigorous clinical development. OVVs are viruses that are harmless to healthy cells while targeting and attacking tumor cells. OVVs are made with a specific molecule that is also produced by tumors – because immune cells can recognize the OVV as an invader, they will then be able to recognize the tumor by picking up the commonly shared molecule from the OVV, and denote it as a threat creating a immune response against the tumor. OVVs are also known to induce a molecule known as type I interferon (IFN-I). In non-cancerous conditions, IFN-I induces the maturation of a multitude of immune cells, strengthening an immune response. In cancerous conditions, IFN-I can prevent tumor cell growth by promoting death of said tumor cells. However, it is also seen that IFN-I can also play a negative role during T cell-mediated response. In particular, IFN-I can lead to the creation of a surrounding environment that prevents the immune system from fighting cancer, a mechanism known as immunosuppression and is a significant hurdle in cancer immunotherapy. Recently, it has been demonstrated that IFN-I, despite its role as an immune system mediator, may not be needed during treatment with OVVs and in high concentrations, may be deleterious to the health of the individual. Accordingly, this project will explore the effects of IFN-I on the environment produced by the tumor as well as the effect it has on immune cell function in the context of OVV therapies.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fisher, Robert
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~